Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Esophageal Squamous Cell Carcinoma 8Esophageal Neoplasms 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Nasopharyngeal Carcinoma 6Lung Neoplasms 6Head and Neck Neoplasms 5Gallbladder Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Mesothelioma 4Breast Neoplasms 4Biliary Tract Neoplasms 4Stomach Neoplasms 3Oropharyngeal Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Urinary Bladder Neoplasms 2Osteosarcoma 2Neoplasms 2Endometrial Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Bile Duct Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Thymoma 1Thymic epithelial tumor 1Testicular Neoplasms 1

Interventions

pembrolizumab 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Nonsquamous Non-small Cell Lung Cancer × Cisplatin × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡